Skip to content

Pharmacology & Therapeutics

ISSN 1879-016X

9 papers in the library · 1,233 citations · publishing 2004-2024

Papers

Sort Most recent Most cited

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases

Pharmacology & Therapeutics April 6, 2024 Zarah R. Haniff, Mariia Bocharova, Tim Mantingh et al. 16 citations

Major depression is an established risk factor for subsequent dementia, and depression in late life may also represent a prodromal state of dementia. Considering current challenges in the clinical development of disease modifying therapies for dementia, the focus of research is shifting towards prevention and modification of risk factors to alter the neurodegenerative disease trajectory....

Potential neonatal toxicity of new psychoactive substances.

Pharmacology & Therapeutics August 1, 2023 Ryoichi Fujiwara, Megan Journey, Fatimah Al-Doori et al. 13 citations

Cannabis, cocaine, 3,4-methylenedioxymethamphetamine, and lysergic acid diethylamide are psychoactive substances with a significant increase in consumption during the 21st century due to their popularity in medicinal and recreational use. New psychoactive substances (NPSs) mimic established psychoactive substances. NPSs are known as being natural and safe to consumers; however, they are neither...

Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.

Pharmacology & Therapeutics November 1, 2022 Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al. 62 citations

Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Pharmacology & Therapeutics May 1, 2019 Matthew W Johnson, Peter S. Hendricks, Frederick S. Barrett et al. 520 citations

The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest...

The neuropsychopharmacology of cannabis: A review of human imaging studies

Pharmacology & Therapeutics October 20, 2018 Michael Bloomfield, Chandni Hindocha, Sebastian F Green et al. 236 citations

receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of...

Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?

Pharmacology & Therapeutics February 1, 2018 Laura Hondebrink, Anne Zwartsen, Remco H S Westerink 78 citations

The use of new psychoactive substances (NPS) is increasing and currently >600 NPS have been reported. However, limited information on neuropharmacological and toxicological effects of NPS is available, hampering risk characterization. We reviewed the literature on the in vitro neuronal modes of action to obtain effect fingerprints of different classes of illicit drugs and NPS. The most...

Hallucinogens and dissociative agents naturally growing in the United States.

Pharmacology & Therapeutics May 1, 2004 John H. Halpern 209 citations

It is usually believed that drugs of abuse are smuggled into the United States or are clandestinely produced for illicit distribution. Less well known is that many hallucinogens and dissociative agents can be obtained from plants and fungi growing wild or in gardens. Some of these botanical sources can be located throughout the United States; others have a more narrow distribution. This article...

Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.

Pharmacology & Therapeutics May 1, 2004 Bryan L. Roth, Estela Lopez, Scott Beischel et al. 98 citations

Because psychoactive plants exert profound effects on human perception, emotion, and cognition, discovering the molecular mechanisms responsible for psychoactive plant actions will likely yield insights into the molecular underpinnings of human consciousness. Additionally, it is likely that elucidation of the molecular targets responsible for psychoactive drug actions will yield validated...

Hallucinogens.

Pharmacology & Therapeutics February 1, 2004 David E Nichols 1 citation

Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous...